Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Pancreatic Cancer | Research

Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway

Authors: Jiewei Lin, Shuyu Zhai, Siyi Zou, Zhiwei Xu, Jun Zhang, Lingxi Jiang, Xiaxing Deng, Hao Chen, Chenghong Peng, Jiaqiang Zhang, Baiyong Shen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Background

FLVCR1-AS1 is a key regulator of cancer progression. However, the biological functions and underlying molecular mechanisms of pancreatic cancer (PC) remain unknown.

Methods

FLVCR1-AS1 expression levels in 77 PC tissues and matched non-tumor tissues were analyzed by qRT-PCR. Moreover, the role of FLVCR1-AS1 in PC cell proliferation, cell cycle, and migration was verified via functional in vitro and in vivo experiments. Further, the potential competitive endogenous RNA (ceRNA) network between FLVCR1-AS1 and KLF10, as well as FLVCR1-AS1 transcription levels, were investigated.

Results

FLVCR1-AS1 expression was low in both PC tissues and PC cell lines, and FLVCR1-AS1 downregulation was associated with a worse prognosis in patients with PC. Functional experiments demonstrated that FLVCR1-AS1 overexpression significantly suppressed PC cell proliferation, cell cycle, and migration both in vitro and in vivo. Mechanistic investigations revealed that FLVCR1-AS1 acts as a ceRNA to sequester miR-513c-5p or miR-514b-5p from the sponging KLF10 mRNA, thereby relieving their suppressive effects on KLF10 expression. Additionally, FLVCR1-AS1 was shown to be a direct transcriptional target of KLF10.

Conclusions

Our research suggests that FLVCR1-AS1 plays a tumor-suppressive role in PC by inhibiting proliferation, cell cycle, and migration through a positive feedback loop with KLF10, thereby providing a novel therapeutic strategy for PC treatment.

Available only for authorised users

Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388:73–85. https://doi.org/10.1016/S0140-6736(16)00141-0.CrossRefPubMed

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2017;67:7–30. https://doi.org/10.3322/caac.21387.

Chiorean EG, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther. 2015;9:3529–45. https://doi.org/10.2147/DDDT.S60328.CrossRefPubMedPubMedCentral

Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8. https://doi.org/10.1038/nature11233.CrossRefPubMedPubMedCentral

Hua Q, Jin M, Mi B, Xu F, Li T, Zhao L, et al. LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis. J Hematol Oncol. 2019;12:91. https://doi.org/10.1186/s13045-019-0773-y.CrossRefPubMedPubMedCentral

Xu M, Chen X, Lin K, Zeng K, Liu X, Xu X, et al. lncRNA SNHG6 regulates EZH2 expression by sponging miR-26a/b and miR-214 in colorectal cancer. J Hematol Oncol. 2019;12:3. https://doi.org/10.1186/s13045-018-0690-5.CrossRefPubMedPubMedCentral

Vennin C, Spruyt N, Robin YM, Chassat T, Le Bourhis X, Adriaenssens E. The long non-coding RNA 91H increases aggressive phenotype of breast cancer cells and up-regulates H19/IGF2 expression through epigenetic modifications. Cancer Lett. 2017;385:198–206. https://doi.org/10.1016/j.canlet.2016.10.023.CrossRefPubMed

Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452–63. https://doi.org/10.1016/j.ccell.2016.03.010.CrossRefPubMedPubMedCentral

Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes. Mol Cancer. 2020;19:118. https://doi.org/10.1186/s12943-020-01237-y.CrossRefPubMedPubMedCentral

10.

Li N, Yang G, Luo L, Ling L, Wang X, Shi L, et al. lncRNA THAP9-AS1 promotes pancreatic ductal adenocarcinoma growth and leads to a poor clinical outcome via sponging miR-484 and interacting with YAP. Clin Cancer Res. 2020;26:1736–48. https://doi.org/10.1158/1078-0432.CCR-19-0674.CrossRefPubMed

11.

Chen LL. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761–72. https://doi.org/10.1016/j.tibs.2016.07.003.CrossRefPubMed

12.

Peng Z, Wang J, Shan B, Li B, Peng W, Dong Y, et al. The long noncoding RNA LINC00312 induces lung adenocarcinoma migration and vasculogenic mimicry through directly binding YBX1. Mol Cancer. 2018;17:167. https://doi.org/10.1186/s12943-018-0920-z.CrossRefPubMedPubMedCentral

13.

Lin H, Shangguan Z, Zhu M, Bao L, Zhang Q, Pan S. lncRNA FLVCR1-AS1 silencing inhibits lung cancer cell proliferation, migration, and invasion by inhibiting the activity of the Wnt/β-catenin signaling pathway. J Cell Biochem. 2019;120:10625–32. https://doi.org/10.1002/jcb.28352.CrossRefPubMed

14.

Pan Z, Ding J, Yang Z, Li H, Ding H, Chen Q. LncRNA FLVCR1-AS1 promotes proliferation, migration and activates Wnt/β-catenin pathway through miR-381-3p/CTNNB1 axis in breast cancer. Cancer Cell Int. 2020;20:214. https://doi.org/10.1186/s12935-020-01247-2.CrossRefPubMedPubMedCentral

15.

Yan H, Li H, Silva MA, Guan Y, Yang L, Zhu L, et al. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer. J Exp Clin Cancer Res. 2019;38:356. https://doi.org/10.1186/s13046-019-1356-z.CrossRefPubMedPubMedCentral

16.

Chen F, Xu B, Li J, Yang X, Gu J, Yao X, et al. Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10. J Exp Clin Cancer Res. 2021;40:38. https://doi.org/10.1186/s13046-021-01834-9.CrossRefPubMedPubMedCentral

17.

Jiang L, Chen Y, Chan CY, Wang X, Lin L, He ML, et al. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett. 2009;274:101–8. https://doi.org/10.1016/j.canlet.2008.09.017.CrossRefPubMed

18.

Li Z, Hong S, Liu Z, Linc LR. LncRNA LINC00641 Predicts prognosis and inhibits bladder cancer progression through miR-197-3p/KLF10/PTEN/PI3K/AKT cascade. Biochem Biophys Res Commun. 2018;503:1825–9. https://doi.org/10.1016/j.bbrc.2018.07.120.CrossRefPubMed

19.

Yang N, Chen J, Zhang H, Wang X, Yao H, Peng Y, et al. LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. Cell Death Dis. 2017;8:e2975. https://doi.org/10.1038/cddis.2017.358.CrossRefPubMedPubMedCentral

20.

Hua K, Deng X, Hu J, Ji C, Yu Y, Li J, et al. Long noncoding RNA HOST2, working as a competitive endogenous RNA, promotes STAT3-mediated cell proliferation and migration via decoying of let-7b in triple-negative breast cancer. J Exp Clin Cancer Res. 2020;39:58. https://doi.org/10.1186/s13046-020-01561-7.CrossRefPubMedPubMedCentral

21.

Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407. https://doi.org/10.1016/j.cell.2018.01.011.CrossRefPubMedPubMedCentral

22.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395–406. https://doi.org/10.1056/NEJMoa1809775.CrossRefPubMed

23.

Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87. https://doi.org/10.1038/onc.2011.621.CrossRefPubMedPubMedCentral

24.

Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61. https://doi.org/10.1038/nm.3981.CrossRefPubMed

25.

Huang F, Chen W, Peng J, Li Y, Zhuang Y, Zhu Z, et al. LncRNA PVT1 triggers cyto-protective autophagy and promotes pancreatic ductal adenocarcinoma development via the miR-20a-5p/ULK1 Axis. Mol Cancer. 2018;17:98. https://doi.org/10.1186/s12943-018-0845-6.CrossRefPubMedPubMedCentral

26.

Zhai S, Xu Z, Xie J, Zhang J, Wang X, Peng C, et al. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. Oncogene. 2021;40:277–91. https://doi.org/10.1038/s41388-020-01525-3.CrossRefPubMed

27.

Zhang K, Zhao Z, Yu J, Chen W, Xu Q, Chen L. LncRNA FLVCR1-AS1 acts as miR-513c sponge to modulate cancer cell proliferation, migration, and invasion in hepatocellular carcinoma. J Cell Biochem. 2018;119:6045–56. https://doi.org/10.1002/jcb.26802.CrossRefPubMed

28.

Gao X, Zhao S, Yang X, Zang S, Yuan X. Long non-coding RNA FLVCR1-AS1 contributes to the proliferation and invasion of lung cancer by sponging miR-573 to upregulate the expression of E2F transcription factor 3. Biochem Biophys Res Commun. 2018;505:931–8. https://doi.org/10.1016/j.bbrc.2018.09.057.CrossRefPubMed

29.

Liu Y, Guo G, Zhong Z, Sun L, Liao L, Wang X, et al. Long non-coding RNA FLVCR1-AS1 sponges miR-155 to promote the tumorigenesis of gastric cancer by targeting c-Myc. Am J Transl Res. 2019;11:793–805.PubMedPubMedCentral

30.

Bao W, Cao F, Ni S, Yang J, Li H, Su Z, et al. lncRNA FLVCR1-AS1 regulates cell proliferation, migration and invasion by sponging miR-485-5p in human cholangiocarcinoma. Oncol Lett. 2019;18:2240–7. https://doi.org/10.3892/ol.2019.10577.CrossRefPubMedPubMedCentral

31.

Liu P, Zhao P, Li B, Xu D, Wang K. LncRNA PCAT6 regulated by YY1 accelerates the progression of glioblastoma via miR-513/IGF2BP1. Neurochem Res. 2020;45:2894–902. https://doi.org/10.1007/s11064-020-03138-4.CrossRefPubMed

32.

Liu X, Peng D, Cao Y, Zhu Y, Yin J, Zhang G, et al. Upregulated lncRNA DLX6-AS1 underpins hepatocellular carcinoma progression via the miR-513c/Cul4A/ANXA10 axis. Cancer Gene Ther. 2020. https://doi.org/10.1038/s41417-020-00233-0.CrossRefPubMedPubMedCentral

33.

Xia HL, Lv Y, Xu CW, Fu MC, Zhang T, Yan XM, et al. MiR-513c suppresses neuroblastoma cell migration, invasion, and proliferation through direct targeting glutaminase (GLS). Cancer Biomark. 2017;20:589–96. https://doi.org/10.3233/CBM-170577.CrossRefPubMed

34.

Ren LL, Yan TT, Shen CQ, Tang JY, Kong X, Wang YC, et al. The distinct role of strand-specific miR-514b-3p and miR-514b-5p in colorectal cancer metastasis. Cell Death Dis. 2018;9:687. https://doi.org/10.1038/s41419-018-0732-5.CrossRefPubMedPubMedCentral

35.

Memon A, Lee WK. KLF10 as a tumor suppressor gene and its TGF-β signaling. Cancers (Basel) 2018;10. https://doi.org/10.3390/cancers10060161.

36.

Xiong Y, Svingen PA, Sarmento OO, Smyrk TC, Dave M, Khanna S, et al. Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. Am J Physiol Regul Integr Comp Physiol. 2014;307:R608-20. https://doi.org/10.1152/ajpregu.00085.2014.CrossRefPubMedPubMedCentral

37.

Jiang L, Lai YK, Zhang JF, Chan CY, Lu G, Lin MC, et al. Transactivation of the TIEG1 confers growth inhibition of transforming growth factor-β-susceptible hepatocellular carcinoma cells. World J Gastroenterol. 2012;18:2035–42. https://doi.org/10.3748/wjg.v18.i17.2035.CrossRefPubMedPubMedCentral

Title: Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway
Authors: Jiewei Lin
Shuyu Zhai
Siyi Zou
Zhiwei Xu
Jun Zhang
Lingxi Jiang
Xiaxing Deng
Hao Chen
Chenghong Peng
Jiaqiang Zhang
Baiyong Shen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Pancreatic Cancer
Pancreatic Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02097-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Radiation induces NORAD expression to promote ESCC radiotherapy resistance via EEPD1/ATR/Chk1 signalling and by inhibiting pri-miR-199a1 processing and the exosomal transfer of miR-199a-5p

Cancer-associated fibroblasts promote the survival of irradiated nasopharyngeal carcinoma cells via the NF-κB pathway

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy

Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy

A novel lncRNA ARST represses glioma progression by inhibiting ALDOA-mediated actin cytoskeleton integrity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer